Department of Surgery, Division of Urology, Duke University Medical Center , Durham, North Carolina 27710, USA.
J Endourol. 2011 Aug;25(8):1353-7. doi: 10.1089/end.2011.0041. Epub 2011 Jul 8.
Hemostatic agents have been suggested as an adjunct for tubeless percutaneous nephrolithotomy (PCNL). We pathologically evaluated the percutaneous tracts injected with the fibrin sealant (FS) Evicel and hemostatic gelatin matrix (HGM) Surgiflo at various time intervals to determine their absorption and tract closure rates. We also evaluated whether these agents reduced urine leak rates in a porcine model.
Percutaneous access was obtained in 19 kidneys in 10 domestic swine. The tracts were dilated to 30F using a balloon dilating catheter. Ten kidneys served as controls. Surgiflo was injected into the tract of four kidneys, and Evicel was injected into the tract of five kidneys. Intravenous urography (IVU) was performed on postoperative days (POD) 1 and 10 to 14. IVU was performed on two pigs at POD 30. The pigs were sacrificed and kidneys were harvested for pathologic evaluation.
Two (20%) control kidneys had a urine leak on IVU on POD 1. None of the kidneys treated with HGM or FS had a urine leak on POD 1. None of the kidneys had a leak on POD 10 to 14 or POD 30. On pathologic inspection, the tracts of all the control kidneys and HGM kidneys had closed completely at POD 14. Two kidneys treated with FS had fistula at POD 6 and POD 14. At POD 30, the tracts in the control kidneys and kidney treated with HGM had completely healed. Fibrin sealant remained in the tract at POD 30.
Fibrin sealant should be used with caution because it can persist in the tract for up to 30 days and may inhibit wound healing. Hemostatic gelatin matrix is the preferable agent because the tract closed by POD 10 to 14, similar to the findings in the control animals. The use of hemostatic agents in a nephroscopy tract may reduce the risk of early urine leak after tubeless PCNL.
有研究提出使用止血剂作为经皮肾镜碎石取石术(PCNL)无管化的辅助手段。本研究通过对经皮肾通道注射纤维蛋白密封剂(FS)Evicel 和止血明胶基质(HGM)Surgiflo 后不同时间间隔的病理评估,来确定其吸收和通道闭合率。我们还评估了这些药物是否能降低猪模型中的尿漏率。
在 10 头家猪的 19 个肾脏中进行了经皮入路。使用球囊扩张导管将通道扩张至 30F。10 个肾脏作为对照组。4 个肾脏的通道内注射 Surgiflo,5 个肾脏的通道内注射 Evicel。术后第 1 天和第 10 至 14 天行静脉尿路造影(IVU)检查。第 30 天对 2 只猪进行 IVU。处死猪并采集肾脏进行病理评估。
2 个(20%)对照组的肾脏在术后第 1 天的 IVU 检查中出现尿漏。接受 HGM 或 FS 治疗的肾脏在术后第 1 天均无尿漏。术后第 10 至 14 天或第 30 天无肾脏漏尿。病理检查发现,所有对照组和 HGM 治疗组的通道在术后第 14 天已完全闭合。2 个接受 FS 治疗的肾脏在术后第 6 天和第 14 天出现瘘管。第 30 天,对照组和 HGM 治疗组的通道已完全愈合。术后第 30 天,通道内仍有纤维蛋白密封剂。
纤维蛋白密封剂的使用应谨慎,因为它可能在通道中停留长达 30 天,并可能抑制伤口愈合。止血明胶基质是更优选的药物,因为通道在术后第 10 至 14 天关闭,类似于对照组动物的发现。在无管化 PCNL 后,使用止血剂可降低早期尿漏的风险。